Singapore markets close in 5 hours 8 minutes

Bruker Corporation (BRKR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
70.09-8.94 (-11.31%)
At close: 04:00PM EDT
70.58 +0.49 (+0.70%)
After hours: 06:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close79.03
Open74.86
Bid69.98 x 400
Ask70.11 x 100
Day's range68.89 - 74.86
52-week range53.79 - 94.86
Volume3,291,310
Avg. volume875,060
Market cap10.187B
Beta (5Y monthly)1.18
PE ratio (TTM)24.17
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.20 (0.25%)
Ex-dividend date29 Feb 2024
1y target estN/A
All
News
  • Business Wire

    Bruker Reports First Quarter 2024 Financial Results

    BILLERICA, Mass., May 02, 2024--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024.

  • Business Wire

    Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

    TORINO, Italy, May 02, 2024--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup ("ELITech") for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue.

  • Business Wire

    Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

    BARCELONA, Spain, April 26, 2024--At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions.